162 related articles for article (PubMed ID: 24171036)
1. P53 and expression of immunological markers may identify early stage thyroid tumors.
Marcello MA; Morari EC; Cunha LL; De Nadai Silva AC; Carraro DM; Carvalho AL; Soares FA; Vassallo J; Ward LS
Clin Dev Immunol; 2013; 2013():846584. PubMed ID: 24171036
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer.
Lu J; Xu Y; Wu Y; Huang XY; Xie JW; Wang JB; Lin JX; Li P; Zheng CH; Huang AM; Huang CM
BMC Cancer; 2019 Sep; 19(1):920. PubMed ID: 31521128
[TBL] [Abstract][Full Text] [Related]
3. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma.
Cunha LL; Morari EC; Guihen AC; Razolli D; Gerhard R; Nonogaki S; Soares FA; Vassallo J; Ward LS
Clin Endocrinol (Oxf); 2012 Dec; 77(6):918-25. PubMed ID: 22738343
[TBL] [Abstract][Full Text] [Related]
4. CD8+ TIL recruitment may revert the association of MAGE A3 with aggressive features in thyroid tumors.
Martins MB; Marcello MA; Batista Fde A; Cunha LL; Morari EC; Soares FA; Vassallo J; Ward LS
J Immunol Res; 2014; 2014():921864. PubMed ID: 25825704
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of the imunohistochemical co-expression of p53 and MDM2 in thyroid follicular lesions.
Martins MB; de Assis Batista F; Marcello MA; Bufalo NE; Peres KC; Morari EC; Soares FA; Vassallo J; Ward LS
Ann Diagn Pathol; 2021 Aug; 53():151766. PubMed ID: 34111705
[TBL] [Abstract][Full Text] [Related]
6. CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer.
Cunha LL; Marcello MA; Nonogaki S; Morari EC; Soares FA; Vassallo J; Ward LS
Clin Endocrinol (Oxf); 2015 Aug; 83(2):246-53. PubMed ID: 25130519
[TBL] [Abstract][Full Text] [Related]
7. Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation.
Cunha LL; Marcello MA; Morari EC; Nonogaki S; Conte FF; Gerhard R; Soares FA; Vassallo J; Ward LS
Endocr Relat Cancer; 2013 Feb; 20(1):103-10. PubMed ID: 23193072
[TBL] [Abstract][Full Text] [Related]
8. p53 Activation Effect in the Balance of T Regulatory and Effector Cell Subsets in Patients With Thyroid Cancer and Autoimmunity.
Arena A; Stigliano A; Belcastro E; Giorda E; Rosado MM; Grossi A; Assenza MR; Moretti F; Fierabracci A
Front Immunol; 2021; 12():728381. PubMed ID: 34539667
[TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
Bastman JJ; Serracino HS; Zhu Y; Koenig MR; Mateescu V; Sams SB; Davies KD; Raeburn CD; McIntyre RC; Haugen BR; French JD
J Clin Endocrinol Metab; 2016 Jul; 101(7):2863-73. PubMed ID: 27045886
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status.
Chung YR; Kim HJ; Jang MH; Park SY
Breast Cancer Res Treat; 2017 Feb; 161(3):409-420. PubMed ID: 27913931
[TBL] [Abstract][Full Text] [Related]
12. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer.
Nielsen JS; Sahota RA; Milne K; Kost SE; Nesslinger NJ; Watson PH; Nelson BH
Clin Cancer Res; 2012 Jun; 18(12):3281-92. PubMed ID: 22553348
[TBL] [Abstract][Full Text] [Related]
13. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
14. Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer.
Wouters MC; Komdeur FL; Workel HH; Klip HG; Plat A; Kooi NM; Wisman GB; Mourits MJ; Arts HJ; Oonk MH; Yigit R; de Jong S; Melief CJ; Hollema H; Duiker EW; Daemen T; de Bruyn M; Nijman HW
Clin Cancer Res; 2016 Feb; 22(3):714-24. PubMed ID: 26384738
[TBL] [Abstract][Full Text] [Related]
15. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
[TBL] [Abstract][Full Text] [Related]
16. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
18. Alterations of p53 and expression of WAF1/p21 in human thyroid tumors.
Zedenius J; Larsson C; Wallin G; Bäckdahl M; Aspenblad U; Höög A; Børresen AL; Auer G
Thyroid; 1996 Feb; 6(1):1-9. PubMed ID: 8777377
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer.
Melck A; Masoudi H; Griffith OL; Rajput A; Wilkins G; Bugis S; Jones SJ; Wiseman SM
Ann Surg Oncol; 2007 Dec; 14(12):3403-11. PubMed ID: 17882495
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.
Pavelić K; Dedivitis RA; Kapitanović S; Cacev T; Guirado CR; Danić D; Radosević S; Brkić K; Pegan B; Krizanac S; Kusić Z; Spaventi S; Bura M
Mutat Res; 2006 Jul; 599(1-2):45-57. PubMed ID: 16698048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
